Advertisement
Singapore markets closed

  • Straits Times Index

    3,293.13
    +20.41 (+0.62%)
     

  • S&P 500

    5,078.65
    +8.10 (+0.16%)
     

  • Dow

    38,461.45
    -42.24 (-0.11%)
     

  • Nasdaq

    15,785.44
    +88.80 (+0.57%)
     

  • Bitcoin USD

    66,073.84
    -799.67 (-1.20%)
     

  • CMC Crypto 200

    1,426.01
    +1.91 (+0.13%)
     

  • FTSE 100

    8,057.28
    +12.47 (+0.15%)
     

  • Gold

    2,332.60
    -9.50 (-0.41%)
     

  • Crude Oil

    82.94
    -0.42 (-0.50%)
     

  • 10-Yr Bond

    4.6480
    +0.0500 (+1.09%)
     

  • Nikkei

    38,460.08
    +907.92 (+2.42%)
     

  • Hang Seng

    17,201.27
    +372.34 (+2.21%)
     

  • FTSE Bursa Malaysia

    1,571.48
    +9.84 (+0.63%)
     

  • Jakarta Composite Index

    7,174.53
    +63.72 (+0.90%)
     

  • PSE Index

    6,572.75
    +65.95 (+1.01%)
     

Better Long-Term Buy: AbbVie or Novo Nordisk?

Jim Halley, The Motley Fool
·5-min read
Better Long-Term Buy: AbbVie or Novo Nordisk?

Pharmaceutical companies Novo Nordisk (NYSE: NVO) and AbbVie (NYSE: ABBV) seem to be headed in separate directions. Denmark-based Novo Nordisk, thanks to growing sales of diabetes drug Ozempic and obesity therapy Wegovy, is predicting sales to grow between 24% to 30% and operating profit to rise 28% to 34% this year. AbbVie, on the other hand, thanks to the loss of patent protection for immunology blockbuster Humira, has forecasted 2023 adjusted earnings per share (EPS) to drop by 20% to 23%, from 2022 levels.

Continue reading